Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy

Nat Commun. 2024 May 8;15(1):3860. doi: 10.1038/s41467-024-47835-y.

Abstract

Dual blocker therapy (DBT) has the enhanced antitumor benefits than the monotherapy. Yet, few effective biomarkers are developed to monitor the therapy response. Herein, we investigate the DBT longitudinal plasma proteome profiling including 113 longitudinal samples from 22 patients who received anti-PD1 and anti-CTLA4 DBT therapy. The results show the immune response and cholesterol metabolism are upregulated after the first DBT cycle. Notably, the cholesterol metabolism is activated in the disease non-progressive group (DNP) during the therapy. Correspondingly, the clinical indicator prealbumin (PA), free triiodothyronine (FT3) and triiodothyronine (T3) show significantly positive association with the cholesterol metabolism. Furthermore, by integrating proteome and radiology approach, we observe the high-density lipoprotein partial remodeling are activated in DNP group and identify a candidate biomarker APOC3 that can reflect DBT response. Above, we establish a machine learning model to predict the DBT response and the model performance is validated by an independent cohort with balanced accuracy is 0.96. Thus, the plasma proteome profiling strategy evaluates the alteration of cholesterol metabolism and identifies a panel of biomarkers in DBT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / blood
  • CTLA-4 Antigen / metabolism
  • Cholesterol* / blood
  • Cholesterol* / metabolism
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immune Checkpoint Inhibitors / therapeutic use
  • Machine Learning
  • Male
  • Middle Aged
  • Neoplasms / blood
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Programmed Cell Death 1 Receptor / blood
  • Programmed Cell Death 1 Receptor / metabolism
  • Proteome* / metabolism
  • Proteomics / methods
  • Triiodothyronine / blood

Substances

  • Cholesterol
  • Proteome
  • CTLA-4 Antigen
  • Programmed Cell Death 1 Receptor
  • Biomarkers
  • CTLA4 protein, human
  • PDCD1 protein, human
  • Triiodothyronine
  • Immune Checkpoint Inhibitors